Lung cancer study aims to uncover why tumors progress and relapse
NCT ID NCT07470476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect tumor samples and medical data from 150 adults with non-small cell lung cancer (stages I to IV) at Bordeaux University Hospital. Researchers will analyze the molecular, metabolic, and immune features of the tumors to understand how the cancer progresses and comes back. The goal is to find patterns that could lead to better ways to predict outcomes and develop new treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify new biomarkers and therapeutic targets for non-small cell lung cancer, potentially leading to better treatments in the future.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants, and findings may not translate into clinical practice for many years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?